Literature DB >> 21457615

The time is crucial for ex vivo expansion of T regulatory cells for therapy.

Natalia Marek1, Maria Bieniaszewska, Adam Krzystyniak, Jolanta Juścińska, Jolanta Myśliwska, Piotr Witkowski, Andrzej Hellmann, Piotr Trzonkowski.   

Abstract

Ex vivo expanded CD4(+)CD25(high)CD127(-) T regulatory cells (Tregs) are recognized as a promising candidate for immunosuppressive therapy in humans. However, due to the plasticity of Tregs lineage and artificial environment present during ex vivo expansion, Tregs easily lose suppressive activity. Here, we followed expanding CD4(+)CD25(high)CD127(-) Tregs and their naive (CD45RA(+)) and memory-like (CD45RA(-)) subsets in order to establish the best conditions of the expansion. We found that, regardless of the phenotype sorted, expanding Tregs were undergoing changes resembling homeostatic proliferation and transformed into effector memory-like cells which produced not only suppressive interleukin-10 (IL-10) but also IL-6, IL-17, and interferon-γ (IFN-γ). With the time ex vivo, Tregs were losing the expression of FoxP3 and suppressive activity both when stimulated and when at rest. The only variable that helped preserve suppressive abilities of Tregs was the limitation of the time of ex vivo cultures to 2 weeks only. According to our study, the highest number of highly suppressive Tregs could be yielded with CD4(+)CD25(high)CD127(-) Tregs cultured no longer than 2 weeks. Thorough quality check, preferentially with the assessment of FoxP3 expression and IFN-γ suppression assay, should be applied to assess suppressive activity of the cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21457615     DOI: 10.3727/096368911X566217

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  25 in total

1.  FOXP3+ regulatory T cell development and function require histone/protein deacetylase 3.

Authors:  Liqing Wang; Yujie Liu; Rongxiang Han; Ulf H Beier; Tricia R Bhatti; Tatiana Akimova; Mark I Greene; Scott W Hiebert; Wayne W Hancock
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

2.  Restimulation After Cryopreservation and Thawing Preserves the Phenotype and Function of Expanded Baboon Regulatory T Cells.

Authors:  Joshua Weiner; Raimon Duran-Struuck; Jonah Zitsman; Leo Buhler; Hugo Sondermeijer; Alicia N McMurchy; Megan K Levings; Megan Sykes; Adam Griesemer
Journal:  Transplant Direct       Date:  2015-02-01

3.  Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.

Authors:  Bryan D Choi; Patrick C Gedeon; James E Herndon; Gary E Archer; Elizabeth A Reap; Luis Sanchez-Perez; Duane A Mitchell; Darell D Bigner; John H Sampson
Journal:  Cancer Immunol Res       Date:  2013-09       Impact factor: 11.151

4.  The influence of bone marrow- and synovium-derived mesenchymal stromal cells from osteoarthritis patients on regulatory T cells in co-culture.

Authors:  S Hagmann; T Gotterbarm; T Müller; A-M Baesig; S Gantz; T Dreher; P W Kämmerer; S Frank; F Zeifang; B Moradi
Journal:  Clin Exp Immunol       Date:  2013-09       Impact factor: 4.330

Review 5.  Promoting transplantation tolerance; adoptive regulatory T cell therapy.

Authors:  N Safinia; J Leech; M Hernandez-Fuentes; R Lechler; G Lombardi
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

6.  Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children.

Authors:  Natalia Marek-Trzonkowska; Malgorzata Mysliwiec; Anita Dobyszuk; Marcelina Grabowska; Ilona Techmanska; Jolanta Juscinska; Magdalena A Wujtewicz; Piotr Witkowski; Wojciech Mlynarski; Anna Balcerska; Jolanta Mysliwska; Piotr Trzonkowski
Journal:  Diabetes Care       Date:  2012-06-20       Impact factor: 19.112

7.  Successful expansion of functional and stable regulatory T cells for immunotherapy in liver transplantation.

Authors:  Niloufar Safinia; Trishan Vaikunthanathan; Henrieta Fraser; Sarah Thirkell; Katie Lowe; Laura Blackmore; Gavin Whitehouse; Marc Martinez-Llordella; Wayel Jassem; Alberto Sanchez-Fueyo; Robert I Lechler; Giovanna Lombardi
Journal:  Oncotarget       Date:  2016-02-16

Review 8.  Improving the Efficacy of Regulatory T Cell Therapy.

Authors:  Paulien Baeten; Lauren Van Zeebroeck; Markus Kleinewietfeld; Niels Hellings; Bieke Broux
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-05       Impact factor: 10.817

9.  Murine CD4⁺CD25⁻ cells activated in vitro with PMA/ionomycin and anti-CD3 acquire regulatory function and ameliorate experimental colitis in vivo.

Authors:  Anna Majowicz; Sander van der Marel; Anje A te Velde; Sybren L Meijer; Harald Petry; Sander J van Deventer; Valerie Ferreira
Journal:  BMC Gastroenterol       Date:  2012-12-03       Impact factor: 3.067

Review 10.  Treatment of graft-versus-host disease with naturally occurring T regulatory cells.

Authors:  Piotr Trzonkowski; Anna Dukat-Mazurek; Maria Bieniaszewska; Natalia Marek-Trzonkowska; Anita Dobyszuk; Jolanta Juścińska; Magdalena Dutka; Jolanta Myśliwska; Andrzej Hellmann
Journal:  BioDrugs       Date:  2013-12       Impact factor: 5.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.